The Neuroendocrine Tumor Research Foundation (NETRF) announced $3.5 million in neuroendocrine tumor (NET) research grants to fund 12 projects around the world in pursuit of more precise treatments.
This round of funding features multiple new fronts for NETRF. The Foundation granted two inaugural Mentored Awards for early career researchers. There were also new areas of NET inquiry. For the first time, NETRF is funding pheochromocytoma and paraganglioma research, including an evaluation of a novel radiotracer for imaging adrenal NETs. NETRF also funded four research projects in lung NETs, an area that has not previously received the attention of other NET sites. NETRF also approved grants to study a potential cause of small intestinal multifocal tumors and to evaluate the role of the gut microbiome in carcinoid syndrome.
Seventy-five percent of the grants were awarded to research institutions that are new to NETRF, including international research at Erasmus MC, University Medical Center Rotterdam, Netherlands; Hebrew University of Jerusalem, Jerusalem, Israel; International Agency for Research on Cancer (IACR-WHO), Lyon, France; Istituto Auxologico Italiano – Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy; and Weizmann Institute of Science, Rehovot, Israel.
Learn more about these new research projects
The NETRF grant process is a competitive and structured peer-reviewed process. The Foundation is currently accepting applications for its next grant cycle. Applications must be received by March 9, 2020.